Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spine Care In Brief

This article was originally published in The Gray Sheet

Executive Summary

ArthroCare deal: Parallax bone access, augmentation and cement injection products exclusive worldwide distribution will commence Nov. 15 under an agreement to acquire parent firm Medical Device Alliance for $28 mil., plus revenue milestone payments. The devices are used in "a variety of orthopedic procedures, including treatments for vertebral compression fractures," the firm says. ArthroCare expects the purchase to close early next year and add $7-$8 mil. to sales. The company simultaneously unveiled its Cavity SpineWand Oct. 24 for use with its Coblation radiofrequency ablation technology to dissolve tissue growths in spinal structures. The device "can be used prior to common procedures including the treatment of spinal diseases requiring bone augmentation and percutaneous cement injection," ArthroCare claims...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel